Literature DB >> 9886072

Hierarchical phosphorylation of recombinant tau by the paired-helical filament-associated protein kinase is dependent on cyclic AMP-dependent protein kinase.

G A Jicha1, A O'Donnell, C Weaver, R Angeletti, P Davies.   

Abstract

Immunoaffinity-purified paired helical filaments (PHFs) from Alzheimer's disease (AD) brain homogenates contain an associated protein kinase activity that is able to induce the phosphorylation of PHF proteins on addition of exogenous MgCl2 and ATP. PHF kinase activity is shown to be present in immunoaffinity-purified PHFs from both sporadic and familial AD, Down's syndrome, and Pick's disease but not from normal brain homogenates. Although initial studies failed to show that the kinase was able to induce the phosphorylation of tau, additional studies presented in this article show that only cyclic AMP-dependent protein kinase-pretreated recombinant tau is a substrate for the PHF kinase activity. Deletional mutagenesis, phosphopeptide mapping, and site-directed mutagenesis have identified the PHF kinase phosphorylation sites as amino acids Thr361 and Ser412 in htau40. In addition, the cyclic AMP-dependent protein kinase phosphorylation sites that direct the PHF kinase have been mapped to amino acids Ser356 and Ser409 in htau40. Additional data demonstrate that these hierarchical phosphorylations in the extreme C terminus of tau allow for the incorporation of recombinant tau into exogenously added AD-derived PHFs, providing evidence that certain unique phosphorylations of tau may play a role in the pathogenesis of neurofibrillary pathology in AD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9886072     DOI: 10.1046/j.1471-4159.1999.0720214.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  24 in total

Review 1.  Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: cause or effect?

Authors:  Dennis W Dickson
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

2.  Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease.

Authors:  Leonel E Rojo; Jans Alzate-Morales; Iván N Saavedra; Peter Davies; Ricardo B Maccioni
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

3.  Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models.

Authors:  Christopher M Acker; Stefanie K Forest; Ray Zinkowski; Peter Davies; Cristina d'Abramo
Journal:  Neurobiol Aging       Date:  2012-06-21       Impact factor: 4.673

Review 4.  14-3-3/Tau Interaction and Tau Amyloidogenesis.

Authors:  Yuwen Chen; Xingyu Chen; Zhiyang Yao; Yuqi Shi; Junwen Xiong; Jingjing Zhou; Zhengding Su; Yongqi Huang
Journal:  J Mol Neurosci       Date:  2019-05-06       Impact factor: 3.444

5.  Methods for measuring tau pathology in transgenic mouse models.

Authors:  Stefanie K Forest; Christopher M Acker; Cristina d'Abramo; Peter Davies
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 6.  Tau Proteins and Tauopathies in Alzheimer's Disease.

Authors:  Fong Ping Chong; Khuen Yen Ng; Rhun Yian Koh; Soi Moi Chye
Journal:  Cell Mol Neurobiol       Date:  2018-01-03       Impact factor: 5.046

7.  Tau gene transfer, but not alpha-synuclein, induces both progressive dopamine neuron degeneration and rotational behavior in the rat.

Authors:  Ronald L Klein; Robert D Dayton; Wen-Lang Lin; Dennis W Dickson
Journal:  Neurobiol Dis       Date:  2005-10       Impact factor: 5.996

8.  The cochaperone BAG2 sweeps paired helical filament- insoluble tau from the microtubule.

Authors:  Daniel C Carrettiero; Israel Hernandez; Pierre Neveu; Thales Papagiannakopoulos; Kenneth S Kosik
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

9.  PET imaging in rats to discern temporal onset differences between 6-hydroxydopamine and tau gene vector neurodegeneration models.

Authors:  Ronald L Klein; Robert D Dayton; Tracee L Terry; Chris Vascoe; John J Sunderland; Kerrie H Tainter
Journal:  Brain Res       Date:  2009-02-10       Impact factor: 3.252

10.  Genetic suppression of β2-adrenergic receptors ameliorates tau pathology in a mouse model of tauopathies.

Authors:  Elena V Wisely; Yang K Xiang; Salvatore Oddo
Journal:  Hum Mol Genet       Date:  2014-03-13       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.